# EDGAR Filing Document

**Accession Number:** 0001633313
**File Stem:** 0001438934-25-000415
**Filing Date:** 2025-7
**Character Count:** 18245
**Document Hash:** ff037d91b77e46a4d1d2a901ca10659d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001438934-25-000415.hdr.sgml**: 20250730

**ACCESSION NUMBER**: 0001438934-25-000415

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250730

**EFFECTIVENESS DATE**: 20250730

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Avoro Capital Advisors LLC
- **CENTRAL INDEX KEY:** 0001633313

**ORGANIZATION NAME:**
- **EIN:** 271007403
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-16573
- **FILM NUMBER:** 251165946

**BUSINESS ADDRESS:**
- **STREET 1:** 110 GREENE STREET
- **STREET 2:** SUITE 800
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10012
- **BUSINESS PHONE:** 212-937-4975

**MAIL ADDRESS:**
- **STREET 1:** 110 GREENE STREET
- **STREET 2:** SUITE 800
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10012

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** venBio Select Advisor LLC
- **DATE OF NAME CHANGE:** 20150210

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001633313

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Avoro Capital Advisors LLC

**Address:** 110 Greene Street, Suite 800, New York, NY 10012

**Telephone number:** (212) 937-4975

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-16573

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                  | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                               | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| 89BIO, INC.                     | 282559103 | 05/28/2025     | Approval of, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |        4348989 |                0 | FOR         |                                  4348989 | FOR                         |  |
| AADI BIOSCIENCE, INC.           | 00032Q104 | 02/28/2025     | Non-Binding Advisory Vote on Golden Parachutes Proposal: To approve, on a non-binding, advisory basis, certain compensation that will or may become payable to our named executive officers in connection with the Divestiture.                                | SECTION 14A SAY-ON-PAY VOTES |        3471752 |                0 | FOR         |                                  3471752 | FOR                         |  |
| ALKERMES PLC                    | G01767105 | 05/21/2025     | To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |        1833880 |                0 | FOR         |                                  1833880 | FOR                         |  |
| AMICUS THERAPEUTICS, INC.       | 03152W109 | 06/05/2025     | Approval, on an advisory basis, the Company's executive compensation.                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |       20500000 |                0 | FOR         |                                 20500000 | FOR                         |  |
| APELLIS PHARMACEUTICALS INC.    | 03753U106 | 06/03/2025     | To hold an advisory vote to approve the compensation paid to our named executive officers.                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |        4944546 |                0 | FOR         |                                  4944546 | FOR                         |  |
| APELLIS PHARMACEUTICALS INC.    | 03753U106 | 06/03/2025     | To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers.                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |        4944546 |                0 | 1 YEAR      |                                  4944546 | FOR                         |  |
| ARGENX SE                       | 04016X101 | 05/27/2025     | The 2024 remuneration report                                                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |         782046 |                0 | FOR         |                                   782046 | FOR                         |  |
| ARROWHEAD PHARMACEUTICALS, INC. | 04280A100 | 03/12/2025     | Advisory Vote to Approve Executive Compensation.                                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |        9936434 |                0 | FOR         |                                  9936434 | FOR                         |  |
| ARROWHEAD PHARMACEUTICALS, INC. | 04280A100 | 03/12/2025     | Advisory Vote on Frequency of Executive Compensation Advisory Votes.                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |        9936434 |                0 | 1 YEAR      |                                  9936434 | FOR                         |  |
| AVIDITY BIOSCIENCES, INC.       | 05370A108 | 06/10/2025     | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                                | SECTION 14A SAY-ON-PAY VOTES |        5500484 |                0 | FOR         |                                  5500484 | FOR                         |  |
| BIOCRYST PHARMACEUTICALS, INC.  | 09058V103 | 06/12/2025     | To hold a non-binding, advisory vote regarding executive compensation.                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |        7568494 |                0 | FOR         |                                  7568494 | FOR                         |  |
| BLUEPRINT MEDICINES CORPORATION | 09627Y109 | 06/18/2025     | Approval of a non-binding advisory vote on the compensation paid to our named executive officers.                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        3863022 |                0 | FOR         |                                  3863022 | FOR                         |  |
| CENTESSA PHARMACEUTICALS PLC    | 152309100 | 06/20/2025     | To re-appoint as a director Arjun Goyal, M.D., M.Phil., M.B.A., who retires by rotation in accordance with the Company's articles of association.                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        4189558 |                0 | FOR         |                                  4189558 | FOR                         |  |
| INTRA-CELLULAR THERAPIES, INC.  | 46116X101 | 03/27/2025     | To approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to ITI's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement. | SECTION 14A SAY-ON-PAY VOTES |         742500 |                0 | FOR         |                                   742500 | FOR                         |  |
| KRYSTAL BIOTECH, INC.           | 501147102 | 05/16/2025     | Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |        2201928 |                0 | FOR         |                                  2201928 | FOR                         |  |
| KYMERA THERAPEUTICS, INC.       | 501575104 | 06/25/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers.                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |        2791209 |                0 | FOR         |                                  2791209 | FOR                         |  |
| MADRIGAL PHARMACEUTICALS INC.   | 558868105 | 06/20/2025     | Advisory vote to approve executive compensation                                                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |         205446 |                0 | FOR         |                                   205446 | FOR                         |  |
| MADRIGAL PHARMACEUTICALS INC.   | 558868105 | 06/20/2025     | Advisory vote to approve the frequency of future advisory votes to approve executive compensation                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |         205446 |                0 | 1 YEAR      |                                   205446 | FOR                         |  |
| MANNKIND CORPORATION            | 56400P706 | 05/14/2025     | To approve, on an advisory basis, the compensation of the named executive officers of MannKind, as disclosed in MannKind's proxy statement for the Annual Meeting.                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         692471 |                0 | FOR         |                                   692471 | FOR                         |  |
| MERUS N.V.                      | N5749R100 | 05/21/2025     | Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |        3155555 |                0 | FOR         |                                  3155555 | FOR                         |  |
| MOONLAKE IMMUNOTHERAPEUTICS     | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |        1172060 |                0 | FOR         |                                  1172060 | FOR                         |  |
| OCULAR THERAPEUTIX, INC.        | 67576A100 | 06/11/2025     | To approve an advisory vote on named executive officer compensation.                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |        7743927 |                0 | FOR         |                                  7743927 | FOR                         |  |
| SAREPTA THERAPEUTICS, INC.      | 803607100 | 06/05/2025     | ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |        2322489 |                0 | FOR         |                                  2322489 | FOR                         |  |
| ULTRAGENYX PHARMACEUTICAL INC.  | 90400D108 | 05/15/2025     | Advisory (non-binding) vote to approve the compensation of our named executive officers.                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |         830000 |                0 | FOR         |                                   830000 | FOR                         |  |
| UNIQURE N.V.                    | N90064101 | 06/11/2025     | Approval, on an advisory basis, of the compensation of the named executive officers of the Company.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |        2465183 |                0 | FOR         |                                  2465183 | FOR                         |  |
| UNITED THERAPEUTICS CORPORATION | 91307C102 | 06/26/2025     | Advisory resolution to approve executive compensation.                                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |        1249329 |                0 | FOR         |                                  1249329 | FOR                         |  |
| VERA THERAPEUTICS, INC.         | 92337R101 | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |        5202377 |                0 | FOR         |                                  5202377 | FOR                         |  |
| VERA THERAPEUTICS, INC.         | 92337R101 | 05/14/2025     | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |        5202377 |                0 | 1 YEAR      |                                  5202377 | FOR                         |  |
| WHITEHAWK THERAPEUTICS, INC.    | 00032Q104 | 06/11/2025     | To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the 'Executive Compensation' section of the proxy statement.                                                           | SECTION 14A SAY-ON-PAY VOTES |        3471752 |                0 | FOR         |                                  3471752 | FOR                         |  |
| XENON PHARMACEUTICALS INC       | 98420N105 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Corporation's named executive officers.                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        5741666 |                0 | FOR         |                                  5741666 | FOR                         |  |
| ZEALAND PHARMA A/S              | K9898X127 | 03/27/2025     | PROPOSAL FROM THE BOARD OF DIRECTORS TO APPROVE THE COMPANY'S REMUNERATION REPORT BY ADVISORY VOTE                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |        1662720 |                0 | FOR         |                                  1662720 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Avoro Capital Advisors LLC

**By (Signature):** Scott Epstein

**By (Printed Signature):** Scott Epstein

**By (Title):** Chief Compliance Officer - Chief Operations Officer

**Date:** 07/30/2025